Long non-coding RNA UCA1 upregulation promotes the migration of hypoxia-resistant gastric cancer cells through the miR-7-5p/EGFR axis

Zichang Yang(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Xiaonan Shi(First Hospital of China Medical University), Xiaojie Zhang(Zhejiang Chinese Medical University), Xiaoxun Wang(First Hospital of China Medical University), Xiujuan Qu(First Hospital of China Medical University), Zhi Li(Central Hospital Affiliated to Shenyang Medical College), Ce Li(Affiliated Hospital of Hebei University), Kezuo Hou(First Hospital of China Medical University), Xiaofang Che(First Hospital of China Medical University), Yibo Fan(The University of Texas MD Anderson Cancer Center)
Experimental Cell Research
May 1, 2018
10.1016/j.yexcr.2018.04.030
Cited by 62

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417